Axel Hauschild
#124,048
Most Influential Person Now
Researcher
Axel Hauschild's AcademicInfluence.com Rankings
Axel Hauschildbiology Degrees
Biology
#7717
World Rank
#10679
Historical Rank
Genetics
#746
World Rank
#838
Historical Rank
Molecular Biology
#913
World Rank
#936
Historical Rank
Download Badge
Biology
Axel Hauschild's Degrees
- Bachelors Biology University of Hamburg
- Masters Molecular Biology University of Hamburg
Similar Degrees You Can Earn
Why Is Axel Hauschild Influential?
(Suggest an Edit or Addition)Axel Hauschild's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Improved survival with vemurafenib in melanoma with BRAF V600E mutation. (2011) (5546)
- Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. (2011) (4157)
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial (2012) (2647)
- Improved overall survival in melanoma with combined dabrafenib and trametinib. (2015) (2115)
- Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. (2014) (1496)
- Management of immune-related adverse events and kinetics of response with ipilimumab. (2012) (1244)
- Efficacy and safety of vismodegib in advanced basal-cell carcinoma. (2012) (1194)
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial (2015) (1097)
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. (2016) (1048)
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma (2017) (964)
- Melanoma (2018) (873)
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. (2012) (819)
- PD‐1 Blockade with Cemiplimab in Advanced Cutaneous Squamous‐Cell Carcinoma (2018) (807)
- Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. (2014) (792)
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. (2019) (692)
- Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. (2013) (681)
- MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. (2013) (578)
- Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. (2009) (541)
- Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects (2011) (519)
- Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial (2008) (474)
- Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. (2004) (467)
- Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study (2017) (462)
- Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. (2017) (426)
- Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016. (2012) (420)
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network (2013) (411)
- Melanoma risk in congenital melanocytic naevi: a systematic review (2006) (395)
- Epidemiology of invasive cutaneous melanoma (2009) (385)
- Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. (2010) (375)
- Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012) (338)
- Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes (2005) (326)
- Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. (2008) (315)
- Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012) (312)
- Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study (2017) (276)
- Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma” (2013) (275)
- Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. (2019) (258)
- Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task. (2019) (257)
- Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. (2014) (246)
- Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. (2017) (229)
- Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma (2010) (225)
- Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. (2012) (219)
- Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. (2020) (212)
- Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. (2015) (211)
- Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T‐cell lymphoma (2003) (209)
- Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. (2017) (206)
- Analysis of dermatologic events in vemurafenib-treated patients with melanoma. (2013) (199)
- Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma (2015) (191)
- Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study (2016) (188)
- A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task. (2019) (183)
- S100B Protein Detection in Serum Is a Significant Prognostic Factor in Metastatic Melanoma (1999) (183)
- Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. (2015) (183)
- Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. (2015) (183)
- Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma (2018) (176)
- Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma (2008) (174)
- Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. (2014) (171)
- Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials (2015) (169)
- Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study (2017) (169)
- Ipilimumab in patients with cancer and the management of dermatologic adverse events. (2014) (166)
- Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. (2010) (166)
- Superior skin cancer classification by the combination of human and artificial intelligence. (2019) (165)
- Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma . (2012) (163)
- Deep neural networks are superior to dermatologists in melanoma image classification. (2019) (156)
- Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety (2014) (155)
- A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma (2003) (148)
- Survival of patients with advanced metastatic melanoma: The impact of novel therapies. (2016) (146)
- Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012. (2012) (145)
- Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. (2020) (143)
- Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. (2017) (141)
- European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. (2020) (137)
- Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. (2008) (135)
- EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. (2008) (132)
- Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study. (1997) (128)
- Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. (2007) (128)
- Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. (2017) (127)
- Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial (2020) (126)
- Surgery and radiotherapy in the treatment of cutaneous melanoma (2009) (126)
- European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019. (2019) (122)
- Systematic outperformance of 112 dermatologists in multiclass skin cancer image classification by convolutional neural networks. (2019) (119)
- Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. (2008) (118)
- Treatment and side effect management of CTLA‐4 antibody therapy in metastatic melanoma (2011) (117)
- Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma (2016) (114)
- European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019. (2020) (112)
- Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermatofibrosarcoma Protuberans: A Multicenter Phase II DeCOG Trial with Long-term Follow-up (2013) (112)
- Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. (2011) (111)
- Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. (2013) (111)
- An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). (2013) (109)
- European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. (2020) (107)
- Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial (2017) (107)
- Optimization of photodynamic therapy with a novel self‐adhesive 5‐aminolaevulinic acid patch: results of two randomized controlled phase III studies (2009) (107)
- Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients. (1999) (107)
- In vitro Drug Sensitivity Predicts Response and Survival after Individualized Sensitivity-Directed Chemotherapy in Metastatic Melanoma: A Multicenter Phase II Trial of the Dermatologic Cooperative Oncology Group (2006) (102)
- Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (101)
- Staging of cutaneous melanoma (2009) (99)
- Practical guidelines for the management of interferon‐α‐2b side effects in patients receiving adjuvant treatment for melanoma (2008) (99)
- Short German guidelines: Malignant melanoma (2008) (99)
- An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma (2008) (98)
- Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. (2021) (96)
- Basal cell carcinoma-treatments for the commonest skin cancer. (2014) (95)
- Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. (2008) (89)
- Small molecules and targeted therapies in distant metastatic disease (2009) (88)
- Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG. (2018) (88)
- Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma (2008) (87)
- MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. (2018) (85)
- Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG) (2001) (85)
- Dermatologic adverse events associated with afatinib: an oral ErbB family blocker (2013) (80)
- Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing (2020) (79)
- Comparing artificial intelligence algorithms to 157 German dermatologists: the melanoma classification benchmark. (2019) (79)
- Melanoma in 2013: Melanoma—the run of success continues (2014) (78)
- Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. (2010) (78)
- Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study (2017) (78)
- Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG) (2003) (77)
- Factors Predictive of the Status of Sentinel Lymph Nodes in Melanoma Patients from a Large Multicenter Database (2011) (77)
- Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion (2020) (76)
- Telomerase activity in melanocytic lesions: A potential marker of tumor biology. (2000) (76)
- A Multimarker Prognostic Assay for Primary Cutaneous Melanoma (2009) (75)
- Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma (2007) (74)
- Long‐term follow‐up of photodynamic therapy with a self‐adhesive 5‐aminolaevulinic acid patch: 12 months data (2010) (73)
- Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma (2016) (70)
- Biomarkers in melanoma (2009) (70)
- Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. (2008) (69)
- Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy. (2013) (68)
- Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. (2020) (68)
- Complete remission of a radio‐resistant cutaneous angiosarcoma of the scalp by systemic treatment with liposomal doxorubicin (2002) (66)
- Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. (2016) (65)
- COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma (2014) (64)
- Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. (2003) (64)
- Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. (2020) (63)
- Immunotherapy of distant metastatic disease (2009) (62)
- A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma. (2015) (61)
- Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors (2011) (61)
- S2k Guidelines for Cutaneous Basal Cell Carcinoma – Part 2: Treatment, Prevention and Follow‐up (2019) (60)
- Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600–Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials (2018) (60)
- Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. (2018) (59)
- Brief S2k guidelines – Cutaneous squamous cell carcinoma (2013) (57)
- Brief S2k guidelines – Basal cell carcinoma of the skin (2013) (57)
- Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. (2014) (57)
- Maintenance therapy in cutaneous T-cell lymphoma: who, when, what? (2007) (56)
- Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts. (2021) (56)
- Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod. (2002) (56)
- Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. (2012) (55)
- S3‐Guideline “Diagnosis, therapy and follow‐up of melanoma” – short version (2013) (55)
- Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. (2006) (54)
- Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma (2015) (54)
- Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitors (2011) (53)
- Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse (2009) (52)
- Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma. (2007) (51)
- Paraneoplastic leukemoid reaction and rapid progression in a patient with malignant melanoma: Establishment of KT293, A novel G-CSF-secreting melanoma cell line (2005) (51)
- Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas. (2014) (51)
- Eruptive vellus hair cysts and steatocystoma multiplex. Variants of one entity? (1996) (51)
- Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients. (2017) (51)
- Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients. (2000) (50)
- To excise or not: impact of MelaFind on German dermatologists’ decisions to biopsy atypical lesions (2014) (50)
- Systemic therapy for metastatic malignant melanoma – from deeply disappointing to bright future? (2008) (50)
- Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma. (2012) (50)
- Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition (2021) (49)
- Prospective evaluation of follow-up in melanoma patients in Germany - results of a multicentre and longitudinal study. (2015) (49)
- European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. (2022) (48)
- S2k Guidelines for Cutaneous Basal Cell Carcinoma – Part 1: Epidemiology, Genetics and Diagnosis (2018) (48)
- Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2008) (47)
- Utility of adjuvant systemic therapy in melanoma (2009) (47)
- Artificial Intelligence in Skin Cancer Diagnostics: The Patients' Perspective (2020) (47)
- KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. (2019) (46)
- Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma (2017) (46)
- Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low‐dose interferon alpha (2007) (45)
- Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab. (2017) (45)
- Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician (2011) (45)
- Short German guidelines: Merkel cell carcinoma (2008) (44)
- Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study (2016) (44)
- A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF‐200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapy (2018) (44)
- Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study (2019) (42)
- Treatment of Actinic Cheilitis Using Photodynamic Therapy with Methylaminolevulinate: Report of Three Cases (2005) (42)
- Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma. (2007) (42)
- Primary Extracutaneous Malignant Melanoma: A Comprehensive Review with Emphasis on Treatment (2004) (40)
- Long-Term Survival Analysis in Metastatic Melanoma: Serum S100B Is an Independent Prognostic Marker and Superior to LDH (2008) (39)
- mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study (2014) (39)
- Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. (2014) (39)
- Cutaneous melanoma: A model to study cancer metastasis (2011) (38)
- Up‐to‐date results on survival of patients with melanoma in Germany (2012) (38)
- Effective photodynamic therapy of actinic keratoses on the head and face with a novel, self‐adhesive 5‐aminolaevulinic acid patch (2009) (38)
- Short German guidelines: Basal cell carcinoma (2008) (37)
- Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. (2017) (37)
- Progression of cutaneous melanoma: implications for treatment (2012) (36)
- 1092PDAN UPDATE ON OVERALL SURVIVAL (OS) AND FOLLOW-ON THERAPIES IN BREAK-3, A PHASE III, RANDOMIZED TRIAL: DABRAFENIB (D) VS. DACARBAZINE (DTIC) IN PATIENTS (PTS) WITH BRAF V600E MUTATION-POSITIVE METASTATIC MELANOMA (MM). (2014) (36)
- Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study. (2013) (36)
- Short German guidelines: Squamous cell carcinoma (2008) (36)
- Melanomas of unknown primary frequently harbor TERT-promoter mutations (2014) (36)
- Melanocytic schwannoma of the cutaneous and subcutaneous tissues: three cases and a review of the literature (2008) (35)
- Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations (2015) (35)
- Molecularly targeted therapy for melanoma (2006) (35)
- Association between the germline MC1R variants and somatic BRAF/NRAS mutations in melanoma tumors. (2010) (35)
- The Neuropeptide Alpha-Melanocyte-Stimulating Hormone Is Critically Involved in the Development of Cytotoxic CD8+ T Cells in Mice and Humans (2010) (35)
- Metastatic Melanoma: Scientific Rationale for Sorafenib Treatment and Clinical Results (2008) (35)
- Depressive Mood Changes and Psychiatric Symptoms During 12-month Low-dose Interferon-α Treatment in Patients With Malignant Melanoma: Results From the Multicenter DeCOG Trial (2010) (35)
- Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma. (2009) (35)
- Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations? (2009) (35)
- Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review. (2013) (34)
- Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease (2016) (34)
- Sentinel Node Dissection Delays Recurrence and Prolongs Melanoma-Related Survival: An Analysis of 673 Patients from a Single Center with Long-Term Follow-Up (2011) (34)
- Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. (2019) (34)
- Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma. (2016) (33)
- Dose-Dependent Development of Depressive Symptoms During Adjuvant Interferon-α Treatment of Patients With Malignant Melanoma (2010) (33)
- Health-related Quality of Life Before and During Adjuvant Interferon-&agr; Treatment for Patients With Malignant Melanoma (DeCOG-Trial) (2011) (33)
- Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient. (2009) (32)
- More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments. (2017) (32)
- Prediction of melanoma evolution in melanocytic nevi via artificial intelligence: A call for prospective data. (2019) (32)
- Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma (2011) (31)
- Artificial Intelligence and Its Effect on Dermatologists’ Accuracy in Dermoscopic Melanoma Image Classification: Web-Based Survey Study (2020) (31)
- Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival? (2013) (31)
- [Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma]. (2003) (30)
- Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma. (2022) (30)
- Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries. (2018) (30)
- Kurzleitlinie – Malignes Melanom der Haut (2006) (29)
- Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. (2017) (29)
- Break-MB: a phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets) (2012) (29)
- Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma (2003) (29)
- Combining CNN-based histologic whole slide image analysis and patient data to improve skin cancer classification. (2021) (29)
- EORTC 18991: Long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma, final results of a randomized phase III trial (2007) (28)
- Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis (2021) (28)
- Integrating first-line treatment options into clinical practice: what’s new in advanced melanoma? (2015) (28)
- Surgical Standards in the Primary Care of Melanoma Patients (2003) (28)
- Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): Longer follow-up. (2020) (28)
- Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma. (2017) (28)
- [Brief guidelines: malignant melanoma of the skin]. (2006) (27)
- Neurocutaneous melanosis: a fatal disease in early childhood. (2009) (27)
- Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. (2014) (26)
- European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. (2022) (26)
- Kissing melanoma or kissing nevus of the penis? (2007) (26)
- Effectiveness and Tolerability of Ipilimumab: Experiences From 198 Patients Included in a Named-Patient Program in Various Daily-Practice Settings and Multiple Institutions (2014) (26)
- Long‐Term Efficacy of Subcutaneous Sweat Gland Suction Curettage for Axillary Hyperhidrosis: A Prospective Gravimetrically Controlled Study (2008) (26)
- Serum S100B and LDH are not useful in predicting the sentinel node status in melanoma patients. (2010) (25)
- A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients (2019) (25)
- Electrochemotherapy in symptomatic melanoma skin metastases: intraindividual comparison with conventional surgery. (2010) (25)
- Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. (2011) (25)
- Distinction of 2 different primary Merkel cell carcinomas in 1 patient by Merkel cell polyomavirus genome analysis. (2010) (25)
- Primary analysis of phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC). (2019) (25)
- Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up. (2019) (25)
- Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient’s choice: a multicentre Dermatologic Cooperative Oncology Group trial (2011) (24)
- Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma. (2010) (24)
- Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. (2019) (24)
- Diagnostic and therapeutic procedures for management of melanoma during pregnancy: risks for the fetus? (2006) (24)
- Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). (2007) (24)
- Hidden Variables in Deep Learning Digital Pathology and Their Potential to Cause Batch Effects: Prediction Model Study (2021) (24)
- Distinct clinicopathological and prognostic features of thin nodular primary melanomas: an international study from 17 centers. (2019) (24)
- Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial. (2015) (23)
- Elevated MIA serum levels are of relevance for management of metastasized malignant melanomas: results of a German multicenter study. (2000) (23)
- Integrating Patient Data Into Skin Cancer Classification Using Convolutional Neural Networks: Systematic Review (2021) (23)
- Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy. (2011) (23)
- Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts (2020) (23)
- Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma (2012) (23)
- A phase II multicenter study on the histone deacetylase (HDAC) inhibitor MS-275, comparing two dosage schedules in metastatic melanoma. (2006) (23)
- Phase I/II study with trabedersen (AP 12009) monotherapy for the treatment of patients with advanced pancreatic cancer, malignant melanoma, and colorectal carcinoma. (2011) (22)
- The sebaceous nevus as part of the Schimmelpenning–Feuerstein–Mims Syndrome – an obvious phacomatosis first documented in 1927 (2003) (22)
- Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis (2020) (22)
- Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM). (2009) (22)
- Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group (2008) (21)
- Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma (2019) (21)
- Intermittent BRAF‐inhibitor therapy is a feasible option: report of a patient with metastatic melanoma (2014) (21)
- Does Basal Cell Carcinoma Belong to the Spectrum of Sorafenib-Induced Epithelial Skin Cancers? (2010) (21)
- Diabetes Mellitus in Cancer Patients Treated with Combination Interleukin 2 and α-Interferon (1995) (21)
- Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - Update 2022. (2022) (21)
- Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT) (2016) (20)
- A phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma (2008) (20)
- FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the “Melanoma Research: a bridge from Naples to the World. Napoli, December 5th–6 th2011” (2012) (20)
- Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives (2020) (20)
- Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM (2019) (20)
- Impact of treatment breaks on vismodegib patient outcomes: Exploratory analysis of the STEVIE study. (2015) (19)
- Treatment of melanoma. (2008) (19)
- Intraoral lesions associated with sebaceous nevus syndrome (2006) (19)
- Robustness of convolutional neural networks in recognition of pigmented skin lesions. (2021) (18)
- Malignant Melanoma and HIV Infection – Aggressive Course despite Immune Reconstitution (2004) (18)
- Vismodegib, a Hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study interim analysis in 300 patients. (2013) (18)
- Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial. (2016) (18)
- Combined treatment with pegylated interferon–α‐2a and dacarbazine in patients with advanced metastatic melanoma (2008) (18)
- Combined interferon-α and interleukin-2 as adjuvant treatment for melanoma (1998) (18)
- Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma. (2011) (17)
- A randomized, open‐label clinical trial of tasisulam sodium versus paclitaxel as second‐line treatment in patients with metastatic melanoma (2014) (17)
- A benchmark for neural network robustness in skin cancer classification. (2021) (17)
- Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macro-metastatic nodes: EADO trial. (2010) (17)
- LBA4_PRCOMBI-V: A RANDOMISED, OPEN-LABEL, PHASE III STUDY COMPARING THE COMBINATION OF DABRAFENIB (D) AND TRAMETINIB (T) WITH VEMURAFENIB (V) AS FIRST-LINE THERAPY IN PATIENTS (PTS) WITH UNRESECTABLE OR METASTATIC BRAF V600E/K MUTATION-POSITIVE CUTANEOUS MELANOMA (2014) (17)
- LBA35OVERALL SURVIVAL AND BIOMARKER RESULTS FROM A PHASE 2 STUDY OF MEK1/2 INHIBITOR BINIMETINIB (MEK162) IN PATIENTS WITH ADVANCED NRAS-MUTANT MELANOMA (2014) (16)
- Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAF V600–mutant melanoma: Five-year analysis of COMBI-AD. (2020) (16)
- Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis (2022) (16)
- [Intralesional treatment of classical Kaposi sarcoma with interferon-alpha]. (1992) (16)
- The Use of Serological Tumor Markers for Malignant Melanoma (1997) (16)
- Who benefits most from adjuvant interferon treatment for melanoma? (2015) (16)
- Varying Mutational Alterations in Multiple Primary Melanomas. (2016) (16)
- Loss of leucocyte common antigen (CD45) on atypical lymphocytes in the localized but not disseminated type of Pagetoid reticulosis (1991) (16)
- Quantification of melanoma-associated molecules in plasma/serum of melanoma patients. (2001) (15)
- Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma. (2010) (15)
- Linear intraoral lesions in the sebaceous nevus syndrome. (2005) (15)
- Fear of cancer progression in patients with stage IA malignant melanoma (2018) (15)
- CO14. A pivotal study evaluating efficacy and safety of the hedgehog pathway inhibitor (HPI) vismodegib (GDC-0449) in patients with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC) (2011) (15)
- Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanoma. (2018) (14)
- Explainable artificial intelligence in skin cancer recognition: A systematic review. (2022) (14)
- Sentinel node biopsy in melanoma (2001) (14)
- Deep learning approach to predict sentinel lymph node status directly from routine histology of primary melanoma tumours. (2021) (14)
- Interdisciplinary management recommendations for toxicity associated with interferon‐alfa therapy (2008) (14)
- DERMA phase III trial of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in patients with MAGE-A3-positive resected stage III melanoma. (2011) (14)
- [Mucous membrane melanomas of the upper aerodigestive tract. An analysis of 34 cases]. (1997) (14)
- Serum levels of hepatocyte growth factor as a potential tumor marker in patients with malignant melanoma (2016) (13)
- Checkpoint inhibitors: a new standard of care for advanced Merkel cell carcinoma? (2016) (13)
- Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology. (2019) (13)
- Melanoma and immunotherapy bridge 2015 (2016) (13)
- An open-label, multicenter safety study of vemurafenib (PLX4032, RO5185426) in patients with metastatic melanoma. (2012) (13)
- Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study (2018) (13)
- Coincident PTCH and BRCA1 germline mutations in a patient with nevoid basal cell carcinoma syndrome and familial breast cancer. (2001) (13)
- Sorafenib and pegylated interferon-alpha-2b in advanced metastatic melanoma: A multicenter phase II DeCOG trial. (2010) (13)
- Melanoma and other skin tumors (2012) (13)
- Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial (2003) (12)
- Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. (2019) (12)
- Current recommendations for prevention and therapy of extravasation reactions in dermato‐oncology (2009) (12)
- Treatment Algorithms in Stage IV Melanoma (2015) (12)
- Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG “GERMELATOX survey”) versus melanoma recurrence to quantify patients’ relative values for adjuvant therapy (2016) (12)
- [Safety margins in the excision of primary malignant melanoma. Proposals based on controlled clinical trials]. (2001) (12)
- Clinical evaluation of 5-S-cysteinyldopa testing using a new and optimized detection system as a tumour marker for malignant melanoma (2002) (12)
- Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: An interim analysis of a randomized phase III study (NCT00226408) (2008) (12)
- The Impact of Multispectral Digital Skin Lesion Analysis on German Dermatologist Decisions to Biopsy Atypical Pigmented Lesions with Clinical Characteristics of Melanoma. (2015) (11)
- Vismodegib for advanced basal cell carcinoma: Duration of response after vismodegib discontinuation and response to vismodegib retreatment upon disease progression. (2014) (11)
- Combined interferon-alpha and interleukin-2 as adjuvant treatment for melanoma. (1998) (11)
- Diagnosis and treatment of melanoma . European consensus-based interdisciplinary guideline e Update 2016 (2016) (11)
- Use of monoclonal antibodies (UCHL1, Ki-B3) against T and B cell antigens in routine paraffin-embedded skin biopsy specimens. (1989) (11)
- Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma (2019) (11)
- Disseminated porokeratosis palmaris and plantaris treated with imiquimod cream to prevent malignancy. (2005) (11)
- Side Effects and Toxicities of Targeted Therapies in Stage IV Melanoma (2015) (11)
- Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha‐2b in metastatic melanoma (phase II DeCOG trial) (2013) (11)
- The evolving field of Dermato‐oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV–UEMS and EORTC Cutaneous Lymphoma Task Force (2020) (11)
- Melanoma early detection and awareness: how countries developing melanoma awareness programs could benefit from melanoma-proficient countries. (2015) (10)
- Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. (2014) (10)
- Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase II trial (IMMUNED) (2019) (10)
- Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF-mutant melanoma. (2018) (10)
- Re-challenge with BRAF-directed treatment: A multi-institutional retrospective study. (2017) (10)
- [Adjuvant drug therapy of malignant melanoma. Current knowledge and multi-center studies in German-speaking countries]. (2000) (10)
- [Cutaneous neuroendocrine carcinoma (Merkel cell carcinoma). Quality Assurance Committee of the German Society of Dermatology and the Professional Organization of German Dermatologists e. V]. (1998) (10)
- Hauschild A, Grob JJ, Demidov LV et al.Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365 (2012) (10)
- Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC) (2019) (10)
- An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. (2019) (10)
- Adjuvant Therapy in Melanoma (1998) (10)
- A randomized, multi-national, non-inferiority, phase III trial to evaluate the safety and efficacy of BF-200 ALA gel versus MAL cream in the treatment of non-aggressive basal cell carcinoma with photodynamic therapy (PDT) (2018) (10)
- Kurzleitlinie – Plattenepithelkarzinom der Haut (2008) (10)
- Escalating therapy of cutaneous side effects of EGFR inhibitors: experience of German reference centers (2012) (10)
- Interim Analysis of Phase 2 Results for Cemiplimab in Patients with Metastatic Basal Cell Carcinoma (mBCC) who Progressed on or are Intolerant to Hedgehog Inhibitors (HHIs) (2021) (10)
- A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma. (2013) (9)
- Multiple squamous cell carcinomas in junctional epidermolysis bullosa: a surgical challenge. (2008) (9)
- Abstract S02-01: Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI) (2020) (9)
- Expanded access programmes: patient interests versus clinical trial integrity. (2015) (9)
- Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroups. (2014) (9)
- A multicentre study of naevus‐associated melanoma vs. de novo melanoma, tumour thickness and body site differences * (2021) (9)
- Primary Analysis of Phase 2 Results for Cemiplimab in Patients (pts) with Locally Advanced Basal Cell Carcinoma (laBCC) who Progress on or are Intolerant to Hedgehog Inhibitors (HHIs) (2021) (9)
- Health-related quality of life (HRQL) in patients with advanced cutaneous squamous cell carcinoma (CSCC) treated with cemiplimab: Post hoc exploratory analyses of a phase II clinical trial. (2020) (9)
- Co-expression of NGF and PD-L1 on tumor-associated immune cells in the microenvironment of Merkel cell carcinoma (2018) (9)
- Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2008) (9)
- [Merkel cell carcinoma: follow-up of 10 patients. Current diagnosis and therapy]. (1997) (9)
- Vismodegib (VISMO), a hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study primary analysis in 1215 patients (pts). (2016) (9)
- Pimecrolimus: a novel treatment for cetuximab-induced papulopustular eruption. (2008) (9)
- Efficacy of interferon alpha 2a in 18 versus 60 months of treatment in patients with primary melanoma of ≥ 1.5 mm tumor thickness: A randomized phase III DeCOG trial (2008) (9)
- Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. (2021) (9)
- Efficacy of vemurafenib in BRAFV600K mutation positive melanoma disease - results from the phase III clinical study BRIM-3. (2011) (9)
- Multiple myeloma first presenting as cutaneous plasmacytoma. (1996) (9)
- Photodynamic therapy simplified: nonprepared, moderate‐grade actinic keratosis lesions respond equally well to 5‐aminolaevulinic acid patch photodynamic therapy as do mild lesions (2015) (9)
- Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Final analysis of a randomized phase III DeCOG-trial (NCT00226408). (2008) (9)
- Vemurafenib improves overall survival compared to dacarbazine in advanced BRAFV600E mutated melanoma: an update from the phase III randomized, open-label, multicenter BRIM3 trial (2011) (9)
- Immunotherapy: Combined immunotherapy—a new standard in metastatic melanoma? (2015) (9)
- Dabrafenib plus trametinib (D + T) as adjuvant treatment of resected BRAF-mutant stage III melanoma: Findings from the COMBI-AD trial analyzed based on AJCC 8 classification. (2018) (9)
- Talimogene laherparepvec (T-VEC) in combination (combo) with ipilimumab (ipi) versus ipi alone for advanced melanoma: 3-year landmark analysis of a randomized, open-label, phase II trial (2019) (9)
- Melanocytic nevi (2011) (9)
- Novel DNA methylation markers with potential prognostic relevance in advanced malignant melanoma identified using COBRA assays (2015) (9)
- Risk evaluation in cutaneous melanoma patients undergoing lymph node dissection: impact of POSSUM. (2011) (8)
- A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL). (2013) (8)
- A phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma: A subanalysis based on BRAF status (2013) (8)
- Formalin-resistant leukocyte surface antigens in the diagnosis of cutaneous malignant lymphomas. (1989) (8)
- 428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs) (2020) (8)
- Diabetes mellitus in cancer patients treated with combination interleukin 2 and alpha-interferon. (1995) (8)
- Willingness to pay for a cure of low-risk melanoma patients in Germany (2018) (8)
- LBA47 Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs) (2020) (8)
- Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study (2019) (8)
- Quality of life in patients receiving high-dose interferon alfa-2b after resected high-risk melanoma. (2009) (8)
- Reply to K.S. Wilson et al. (2013) (8)
- Effective and Tolerable Treatment of Advanced Basal Cell Carcinoma With Vismodegib Despite Renal Insufficiency. (2016) (8)
- Efficacy and safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): ERIVANCE BCC study update. (2012) (8)
- Installation of a network for patients with congenital melanocytic nevi in German‐speaking countries (2008) (8)
- Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. (2022) (7)
- Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response. (2021) (7)
- Repeatable acute rhabdomyolysis with multiple organ dysfunction because of interferon α and dacarbazine treatment in metastatic melanoma (2001) (7)
- Efficacy and Safety of Sonidegib in Adult Patients with Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome): Results from a Phase 2, Double-Blind, Randomized Trial (2020) (7)
- Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial (2022) (7)
- Remarkable remission of a follicular lymphoma treated with rituximab and polychemotherapy (CHOP) (2003) (7)
- Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I-III patients. (2020) (7)
- Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/Kmutation-positive cutaneous melanoma. (2015) (7)
- Guideline Implementation in Merkel Cell Carcinoma: An Example of a Rare Disease (2006) (7)
- Primary analysis of phase 2 results for cemiplimab, a human monoclonal anti-PD-1, in patients with metastatic cutaneous squamous cell carcinoma (mCSCC). (2018) (7)
- Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers. (2017) (7)
- Metastatic melanoma of the tongue arising from oral melanosis. (2008) (7)
- MIKIE: A randomized, double-blind, regimen-controlled, phase II, multicenter study to assess the efficacy and safety of two different vismodegib regimens in patients with multiple basal cell carcinomas. (2014) (7)
- Discrimination between immunoaccessory and phagocytic monocytes/macrophages of the skin in paraffin‐embedded tissue by the monoclonal antibody Ki‐M1P (1993) (7)
- Long-Term Outcomes in Patients With BRAF V 600-Mutant Metastatic Melanoma Receiving Dabrafenib Monotherapy : Analysis From Phase 2 and 3 Clinical Trials (2021) (7)
- Multiple skin metastases of malignant melanoma with unusual clinical and histopathologic features in an immunosuppressed patient. (2008) (7)
- Tropomyosin Receptor Kinase A Expression on Merkel Cell Carcinoma Cells (2017) (6)
- Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM): 1-year OS update. (2010) (6)
- New promises in the adjuvant, and palliative treatment of melanoma. (2007) (6)
- Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma. (2019) (6)
- Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib. (2019) (6)
- Clinicopathologic prognostic markers of survival: an analysis of 259 patients with malignant melanoma ≥1 mm (2009) (6)
- Vemurafenlb Improves Overall Survival Compared to Dacarbazlne In Advanced BRAFV600E-mutated Melanoma: Updated Survival Results From a Phase III Randomised, Open-label, Multlcentre Trial (2011) (6)
- Efficacy and Safety of the Hedgehog Pathway Inhibitor Vismodegib in Patients with Advanced Basal Cell Carcinoma (BCC): 12-Month Erivance BCC Study Update (2012) (6)
- The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians (2018) (6)
- Frontline approach to metastatic BRAF-mutant melanoma diagnosis, molecular evaluation, and treatment choice. (2014) (6)
- Actual practice of melanoma follow‐up and treatment in Germany: results of a prospective, longitudinal cohort study (2015) (5)
- Mikie: A randomized, double-blinded, regimen-controlled, phase 2 study to assess the efficacy and safety of two different vismodegib (VISMO) regimens in patients (pts) with multiple basal cell carcinomas (BCCs). (2016) (5)
- Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries (2020) (5)
- Impact of gene expression profiles on clinical predictors of survival in patients (pts) with BRAFV600-mutated metastatic melanoma (mM). (2017) (5)
- Vismodegib in the treatment of patients with metastatic basal cell carcinoma (mBCC) and distant metastases: Survival in the pivotal phase II and phase I studies. (2014) (5)
- Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAF V600–mutant melanoma. (2017) (5)
- Bexarotene and systemic disease progression in CTCL? (2006) (5)
- Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real‐world conditions in Germany – The non‐interventional study NIELS (2021) (5)
- Suppressed thyroid-stimulating hormone secretion in patients treated with interleukin-2 and interferon-α2b for metastatic melanoma (1994) (5)
- Cerebriform Giant Melanocytic Nevus of the Scalp: Report of Two Cases with Different Surgical Approaches (2002) (5)
- A Pivotal Multicenter Trial Evaluating Efficacy and Safety of the Hedgehog Pathway Inhibitor (HPI) Vismodegib in Patients With Advanced Basal Cell Carcinoma (BCC) (2011) (4)
- [Surgical and adjuvant drug therapy in head and neck cutaneous melanoma]. (2000) (4)
- 433 Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial (2020) (4)
- Recent aspects of medical care of malignant melanoma (2008) (4)
- Double Trouble: Immunotherapy Doublets in Melanoma-Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma. (2022) (4)
- Open-label, multicenter safety study of vemurafenib in patients with BRAFV600 mutation–positive metastatic melanoma. (2013) (4)
- Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment (2022) (4)
- Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers. (2017) (4)
- Quality‐of‐life analysis with intermittent vismodegib regimens in patients with multiple basal cell carcinomas: patient‐reported outcomes from the MIKIE study (2020) (4)
- LBA6_PRCOMBI-AD: Adjuvant dabrafenib (D) plus trametinib (T) for resected stage III BRAF V600E/K–mutant melanoma (2017) (4)
- Individualized therapy of disseminated cancer using malignant melanoma as a model (2006) (4)
- Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials (2020) (4)
- Prognostic subgroups and impact of treatment for post-progression overall survival (ppOS) in patients (pts) with BRAFV600-mutated metastatic melanoma treated with dacarbazine (DTIC) or vemurafenib (VEM) ± cobimetinib (COBI): A pooled analysis (2016) (4)
- Final overall survival from a phase 3 trial of nab-paclitaxel versus dacarbazine (DTIC) in chemotherapy-naive patients with metastatic melanoma. (2014) (4)
- Health-related quality of life measures in melanoma patients receiving pulsed high-dose intravenous interferon alpha 2b (IFNα2b) (2007) (3)
- Identifying prognostic subgroups for outcomes in BRAFV600-mutated metastatic melanoma patients (pts) treated with vemurafenib (V) ± cobimetinib (C): A pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. (2016) (3)
- Photodynamic therapy for actinic keratoses: procedure matters? (2012) (3)
- [Brief guideline--cutaneous neuroendocrine carcinoma (Merkel cell carcinoma]. (2006) (3)
- Garbe C, Hauschild A, Volkenandt M et al.Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res 17:393-399 (2008) (3)
- Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial. (2018) (3)
- Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-Up (2020) (3)
- Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting (2019) (3)
- [Current comments on the dermatological oncology working groups' work on high dose therapy with interferon alpha 2b]. (1999) (3)
- 23 A prospective randomised multi-centre trial for the treatment of primary high-risk melanoma using s.c. interleukin-2 and interferon-alpha (1995) (3)
- Patient-reported outcomes (PROs) in KEYNOTE-002, a randomized study of pembrolizumab vs chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) metastatic melanoma (MEL). (2015) (3)
- Histamine dihydrochloride administered with interleukin-2 increases survival duration in patients with ocular melanoma with liver metastases (2001) (3)
- Pembrolizumab versus placebo as adjuvant therapy in resected high-risk stage II melanoma: Phase 3 KEYNOTE-716 study. (2019) (3)
- Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas. (2011) (3)
- More than 5000 patients with metastatic melanoma in Europe per year do not have access to new life-saving drugs (2016) (3)
- Prospective randomized multicenter trial on the outpatient use of subcutaneous interleukin 2 and interferon ??2b in high risk melanoma patients: 401 (1997) (3)
- Efficacy Outcomes in the Phase 3 COMBI-AD Study of Adjuvant Dabrafenib Plus Trametinib vs Placebo in Patients with Stage III BRAFV600E/K-Mutant Melanoma (2018) (3)
- Metastatic basal cell carcinoma: Differences in survival by site of spread. (2012) (3)
- Regression of a basal cell carcinoma infiltrating the brain after vismodegib therapy (2014) (3)
- Algorithm for the management of metastatic cutaneous melanoma. (2014) (3)
- Interim analysis of STEVIE, a single-arm, open-label, multicentre study to evaluate the safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (2013) (2)
- Diagnosis and treatment of basal cell carcinoma: European consensusebased interdisciplinary guidelines (2019) (2)
- [Temozolomide as therapeutic option for patients with metastatic melanoma and poor prognosis]. (2002) (2)
- Malignant melanoma and Wiedemann-Beckwith syndrome in childhood. (2010) (2)
- 4th International Sentinel Node Congress, 3. - 6. Dezember 2004, Los Angeles (USA) (2005) (2)
- [Side-effects of interferon therapy in their management]. (2000) (2)
- 3342 Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma (BCC) treated with vismodegib in the STEVIE study (2015) (2)
- 787O Adjuvant immunotherapy with nivolumab (NIVO) versus observation in completely resected Merkel cell carcinoma (MCC): Disease-free survival (DFS) results from ADMEC-O, a randomized, open-label phase II trial (2022) (2)
- Rare haematologic and neurologic drug reactions from immune checkpoint inhibition in a responding patient with metastatic anorectal mucosal melanoma. (2021) (2)
- Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO). (2019) (2)
- Meeting report from the “ Melanoma Research : a bridge from Naples to the World . Napoli , December 5 th – 6 th 2011 ” (2012) (2)
- Kurzleitlinie: Malignes Melanom der Haut (2006) (2)
- [Adjuvant interferon-alpha therapy of malignant melanoma. Position of the Dermatologic Oncology Working Group]. (1998) (2)
- 1100P Restricted mean survival time (RMST) and cure-rate modeling in estimating survival benefit with adjuvant dabrafenib (D) plus trametinib (T) treatment in melanoma (2020) (2)
- Imiquimod: Wirkmechanismen und Therapieindikationen (2003) (2)
- [Adjuvant therapy of melanoma. From non-specific immune stimulants into the future]. (2006) (2)
- Giant naevoid syringocystadenoma papilliferum. (2005) (2)
- Diagnosis and Treatment of Melanoma. European Consensus ⴀbased Interdisciplinary Guideline Developed by the Guideline Subcommittee of the (2012) (2)
- Association between complete response and survival in advanced melanoma treated with talimogene laherparepvec (T-VEC) plus ipilimumab (ipi). (2020) (2)
- Comment on 'Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines'. (2020) (2)
- Adjuvant treatment of malignant melanoma (1999) (2)
- Meeting report: consensus from the first and second Global Workshops in Melanoma November 19–20, 2008 (2009) (2)
- Evaluation of the Melanoma Tumor Burden Score (MTBS) in a real-world setting. (2017) (2)
- Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial. (2018) (2)
- Eczematous Malignant Melanoma: A Wolf in Sheep’s Clothing (2009) (2)
- Health-Related Quality of Life (HRQL) in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC) Treated with Cemiplimab: Post Hoc Exploratory Analysis of a Phase 2 Clinical Trial (2020) (2)
- Impact of Prior Lines of Systemic Therapy (PST) on the Efficacy Of Cemiplimab, a Human Monoclonal Anti–PD-1, in Patients (PTS) with Advanced Cutaneous Squamous Cell Carcinoma (CSCC) (2019) (2)
- [Clinical studies with sorafenib (Nexavar) in metastatic melanoma]. (2007) (2)
- Increased risk of immune checkpoint inhibitor-induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma? (2020) (2)
- Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials (2014) (2)
- clinical practice guidelines Melanoma : ESMO Clinical Practice Guidelines for diagnosis , treatment and follow-up (2010) (2)
- [Current aspects of adjuvant therapy of malignant melanoma]. (2010) (2)
- Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany (2022) (2)
- Analysis of serum biomarkers and tumor genetic alterations from a phase II study of lenvatinib in patients with advanced BRAF wild-type melanoma. (2013) (2)
- [Adjuvant systemic treatment of melanoma]. (2011) (1)
- New Aspects in the Chemotherapy of Malignant Melanoma (1997) (1)
- Mutational and immune gene expression profiling at relapse in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (pbo) in the COMBI-AD trial. (2018) (1)
- Treatment of actinic cheilitis using photodynamic therapy: report of three cases (2004) (1)
- A new 5-ALA-patch for the photodynamic therapy of actinic keratoses (2011) (1)
- Giant Basal Cell Carcinoma of the Breast Mimicking Paget’s Disease: Complete Remission after Photodynamic Therapy (2010) (1)
- 789O Neoadjuvant cemiplimab in patients (pts) with stage II–IV (M0) cutaneous squamous cell carcinoma (CSCC): Primary analysis of a phase II study (2022) (1)
- [Modern treatment modalities in actinic keratoses of the skin]. (2006) (1)
- 767O TREATMENT OF PATIENTS WITH ADVANCED REFRACTORY OR RELAPSED MELANOMA IN A PHASE II STUDY OF TREMELIMUMAB (CP-675,206), AN ANTI-CTLA4 MONOCLONAL ANTIBODY (2008) (1)
- Intermittent intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Pooled analysis of two randomized phase III trials (NCT00226408 and ISRCTN75125874) with 980 patients. (2013) (1)
- A prospective monitoring study on the value of LDH and protein S-100B as indicators of progressive disease during adjuvant interferon a treatment in melanoma (2005) (1)
- 22 Final results of two randomized adjuvant trials of DeCOG (2004) (1)
- Multicenter real-world data of adjuvant treatment and disease outcome of patients with melanoma with high-risk of recurrence. (2022) (1)
- Adjuvant therapy with pegylated interferon alfa-2a (PEG-IFN) versus low-dose interferon alfa-2a (IFN) in patients with malignant melanoma in stages IIa(T3a): IIIb (AJCC 2002)—Decog-trial. (2014) (1)
- 819P Efficacy of dabrafenib (D) trametinib (T) plus spartalizumab (S) by baseline site of metastases in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Post hoc analysis of phase III COMBI-i trial (2022) (1)
- Best supportive care in combination with polychemotherapy versus best supportive care alone as second-line therapy in stage IV metastatic melanoma (DeCOG MM-PAL 8) (2007) (1)
- Corrigendum to "Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" [Eur J Cancer 91 (2018) 116-124]. (2018) (1)
- [Malignant melanoma of the uvula and soft palate]. (2005) (1)
- The price of tumor control (2013) (1)
- Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM (2019) (1)
- Multiple painful leiomyomas of the skin: a novel therapy with sympathicolysis? (1997) (1)
- FC10 Sorafenib and pegylated interferon alpha 2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial (2010) (1)
- Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials (2014) (1)
- Immune checkpoint blockade for organ-transplant recipients with cancer: A review. (2022) (1)
- 1066P Extended-dose cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Primary analysis of phase II results (2021) (1)
- [Protocol for optimal therapy of malignant melanoma in the metastatic stage by the Dermatologic Oncology Working Group]. (1996) (1)
- Erratum to: Progression of cutaneous melanoma: implications for treatment (2012) (1)
- Intratumoural cisplatin/epinephrine injectable gel provides palliative tumour control for patients with metastatic melanoma (1999) (1)
- Characteristics of Patients With a Complete Response Treated With Dabrafenib + Trametinib Combination Therapy: Findings From Pooled COMBI-d and COMBI-v 5-Year Analysis (2020) (1)
- Complete response of advanced cutaneous squamous cell and basal cell carcinomas with sequential cemiplimab and sonidegib therapy (2021) (1)
- Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma. (2019) (1)
- Lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with advanced melanoma previously exposed to anti–PD-1/PD-L1 agents: Phase 2 LEAP-004 study. (2019) (1)
- New concepts in chemotherapy of malignant melanoma (1996) (1)
- A phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naive patients (pts) with metastatic melanoma: Analysis of peripheral neuropathy. (2013) (1)
- Prospective comparative study of two rehabilitation schemes in 2354 patients with malignant melanoma (2011) (1)
- Contents of Forthcoming Issues · Themenvorschau (2009) (1)
- [Rationale, visions and limits of Immuno-oncology: Checkpoint inhibition as a new pillar of tumor therapy]. (2015) (1)
- An Open-Label, Multicentre Safety Study of Vemurafenib in Patients with Metastatic Melanoma (2012) (1)
- [Adjuvant therapy of malignant melanoma]. (1999) (1)
- 29 Serum S100β detection predicts therapeutic outcome in metastatic melanoma (1997) (1)
- Could controlling occult cytomegalovirus reactivation with prophylactic valganciclovir prevent immune checkpoint blockade-Related complications? (2021) (1)
- 1092PD AN UPDATE ON OVERALL SURVIVAL (OS) AND FOLLOW-ON (2014) (1)
- Estimation of Distant Metastasis-free Survival in Trials of Adjuvant Therapy for Melanoma. Reply. (2019) (1)
- [Malignant melanoma in adolescents]. (1995) (1)
- Reply to E. Hindié and K.R. Hess. (2019) (1)
- Adjuvant Melanoma Therapy (1997) (1)
- [Immunmodulatory antibodies in the treatment of skin cancer]. (2008) (1)
- Sangtec S100?? is a reliable serum marker for metastatic melanoma: 191 (1997) (1)
- Abstracts of the 6th Congress of the European Association of Dermatologic Oncology 16–19 June 2010, Athens, Greece (2010) (1)
- Quality-of-life (QoL) impairment in melanoma patients receiving high-dose interferon alpha 2b (IFNa2b). (2009) (1)
- [Dramatic remission of a multiple metastasized melanoma caused by chemo-immunotherapy]. (1993) (1)
- 871P Predictive role of neutrophil-lymphocyte ratio (NLR) in patients (pts) with metastatic melanoma: A post hoc exploratory analysis from phase III COMBI-i trial (2022) (1)
- 11.4 Therapie kutaner B-Zell-Lymphome (Cutaneous B-Cell Lymphoma, CBCL) (2010) (0)
- Progression of cutaneous melanoma: implications for treatment (2012) (0)
- Major determinants of delayed access to innovative medicines for metastatic melanoma: The results of Melanoma World Society and European Association of Dermato-Oncology survey. (2018) (0)
- [Meeting report of the 39th Annual Conference of the American Society of Clinical Oncology (ASCO), 5/31-6/3/2003, Chicago, USA]. (2003) (0)
- Drug Targeting in Metastatic Melanoma Interleukin-2 Based Adjuvant Immuno-Therapy for Melanoma Patients (2010) (0)
- PCN1 QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS AND TOXICITY (Q-TWIST) OF FOTEMUSTINE COMPARED WITH DACARBAZINE IN PATIENTS WITH DISSEMINATED MALIGNANT MELANOMA (2007) (0)
- INV 26 DeCOG (Dermatologic Cooperative Oncology Group) melanoma trials in the adjuvant setting (2007) (0)
- Skin Cancer Classification Using Convolutional Neural Networks with Integrated Patient Data: A Systematic Review (Preprint) (2020) (0)
- Artificial Intelligence and Its Effect on Dermatologists’ Accuracy in Dermoscopic Melanoma Image Classification: Web-Based Survey Study (Preprint) (2020) (0)
- Volume Index 2011 (2011) (0)
- Subgroup analysis of patients (pts) with Gorlin syndrome treated with vismodegib (VISMO) in the STEVIE study (2016) (0)
- [Rare cutaneous side effect of vemurafenib : Fever and exanthema 14 days after therapy initiation]. (2021) (0)
- O 02 Clinical characteristics and outcome in patients with multibacillary leprosy treated with 12 months of World Health Organization multidrug therapy multibacillary regimen : a retrospective analysis of 730 patients from India (2013) (0)
- Brain metastases of melanoma: fotemustine compared with its combination to whole brain radiation (1999) (0)
- The GERMELATOX DeCOG-trial: Attitude of German melanoma patients towards toxicity during adjuvant interferon treatment—Differences between the patient's and the physician's perspective. (2015) (0)
- Efficacy of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy. (2021) (0)
- Erratum to: Progression of cutaneous melanoma: implications for treatment (2012) (0)
- Descriptive epidemiology of cutaneous melanoma – A treasure for generating hypotheses (2021) (0)
- Model soups improve performance of dermoscopic skin cancer classifiers. (2022) (0)
- Evaluation of the pharmacokinetic (PK) profile of vismodegib (VISMO) in patients (pts) with multiple basal cell carcinomas (BCCs) across two intermittent treatment regimens in the MIKIE study (2016) (0)
- Abstract CT165: Primary analysis of phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma who progressed on or were intolerant to hedgehog inhibitors (2022) (0)
- Selective electrochemical tumour ablation (SECTA): treatment of multiple skin metastases compared with surgery (2006) (0)
- Current status in melanoma treatment (1993) (0)
- Melanoma and Cutaneous Malignancies Characterization andManagement of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma (2016) (0)
- 464TiP Phase III study of adjuvant encorafenib plus binimetinib vs placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design (2022) (0)
- Editorial Board / Imprint / Innentitel / Inhalt (2016) (0)
- British Photodermatology Group (2017) (0)
- [Working Group on Dermatological Oncology]. (2014) (0)
- 30 years German Dermatologic Cooperative Oncology Group (DeCOG) (2021) (0)
- Vorwort (2014) (0)
- 6.7 Antiangiogenese (2010) (0)
- Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase (2020) (0)
- Abstracts of the British Association of Dermatologists 93rd Annual Meeting. Liverpool, United Kingdom. July 9-11, 2013. (2013) (0)
- Safety data on adjuvant treatment of cutaneous melanoma patients with interferon-alpha2b and pegylated interferon-alpha2b: An interim analysis of 285 patients treated in Germany (2016) (0)
- [Merkel cell tumor of the skin]. (1997) (0)
- Melanoma and immunotherapy bridge 2015 (2016) (0)
- Tyrosinase Fails as an Early Melanoma Progression Marker (1996) (0)
- 11.2 Pseudolymphome (2010) (0)
- Cutaneous Gamma-Delta T-Cell Lymphoma Successfully Treated With Brentuximab Vedotin (2016) (0)
- Cancer Therapy : Clinical Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermato fi brosarcoma Protuberans : AMulticenter Phase II DeCOG Trial with Long-term Follow-up (2014) (0)
- PREDICT phase II: A trial to prospectively validate a gene signature associated with clinical benefit from MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) in patients with unresected metastatic cutaneous melanoma. (2011) (0)
- Prospective center-randomized trial of melanoma surveillance in 3,833 patients: An analysis of the early detection of recurrences (2007) (0)
- Reply to Y. Khakoo et al (2009) (0)
- Follow-up study to prove the prognostic value of P-53, S-100-??, ICAM-1 and 5-S-cysteinyldopa in serum of patients with malignant melanoma: 308 (1997) (0)
- 784O Adjuvant nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma with no evidence of disease (NED): Overall survival (OS) results of IMMUNED, a randomized, double-blind multi-center phase II DeCOG trial (2022) (0)
- Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma (2015) (0)
- P89 Distinction of two different primary Merkel cell carcinomas in one patient by Merkel cell polyomavirus (MCPyV) genome analysis (2010) (0)
- Adjuvant dabrafenib plus trametinib (D + T) versus placebo in patients with resected stage III BRAFV600-mutant melanoma: Updated 5-year distant metastases-free survival (DMFS) analysis of COMBI-AD. (2022) (0)
- [Forward: anti-tumor immunity and tumor immunology]. (2014) (0)
- Restricted Mean Survival Time and Cure-Rate Modeling in Estimating Relapse-Free Survival Benefit With Adjuvant Dabrafenib + Trametinib Treatment in Melanoma (2021) (0)
- BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes. (2022) (0)
- Neo-adjuvant Therapy of Dermatofibrosarcoma protuberans with Imatinib: A multicenter Phase II Study of the ADO (2013) (0)
- 5.3 Retinoide (2010) (0)
- [The adjuvant therapy of malignant melanoma]. (1992) (0)
- Adjuvant Therapy in Resected Melanoma. (2018) (0)
- Subject Index Vol. 56, 1999 (1999) (0)
- A new optimized test to detect 5-S-cysteinyldopa (5-S-CD) in serum of melanoma patients as a tool of tumor progression: 307 (1997) (0)
- Precise Orbit Determination of QZS-1 (2011) (0)
- The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022 (2023) (0)
- Open-label, multicenter, single-arm, phase I, dose-dscalation with efficacy tail extension study of vemurafenib in pediatric patients with surgically incurable and unresectable stage IIIc or IV melanoma harboring BRAFV600 mutations (NCT01519323). (2013) (0)
- Fear of progression in patients with low-risk malignant melanoma. (2017) (0)
- AnalysisofDermatologic Events inVemurafenib-TreatedPatients WithMelanoma (2013) (0)
- [Obituary for Prof. Dr. med. Christiane Voit (Berlin)]. (2015) (0)
- [Amelanotic malignant melanoma of the scalp clinically resembling a proliferating trichilemmal cyst]. (2003) (0)
- The GERMELATOX DeCOG-trial: German melanoma patients and their attitude toward toxicity during adjuvant interferon treatment. (2014) (0)
- [Local tumor control of metastatic Merkel cell carcinoma in a 90-year-old woman]. (2021) (0)
- Abstract 5506: Trabedersen (AP 12009) for the treatment of patients with advanced tumors: A phase I/II study (2011) (0)
- 13.2 Obligate kutane Paraneoplasien (2010) (0)
- Targeted treatment modalities for skin cancer (2010) (0)
- Phase 2 study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Long-term follow-up (2023) (0)
- PA-01 : A Phase 2 , Multicenter , Double-Blind , Randomized , Vehicle Controlled Clinical Study to Assess the Synergistic Effect of a Halobetasol / Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis (2019) (0)
- Sustainable responses in metastatic melanoma patients with/without brain metastases after immunotherapy induced CR. (2019) (0)
- Response to: Comment on 'Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines'. (2020) (0)
- [The 2nd Bad Homburg Expert Colloquium on malignant melanoma and other skin tumors]. (1997) (0)
- Ex-vivo sensitivity-directed combination chemotherapy compared to DTIC monochemotherapy in chemo-naive advanced metastastic melanoma (ChemoSensMM): A multicenter randomized phase-3 DeCOG trial. (2015) (0)
- Vorwort (2016) (0)
- Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial (2023) (0)
- Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 Groups 1, 2, and 3 (2023) (0)
- 07 S-100B and melanoma inhibiting activity (MIA): new prognostic serum markers in patients with malignant melanoma (1999) (0)
- Comparative analysis of metabolic signature from malignant melanoma and uninvolved skin. (2015) (0)
- Hidden Variables in Deep Learning Digital Pathology and Their Potential to Cause Batch Effects: Prediction Model Study (Preprint) (2020) (0)
- Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study (2017) (0)
- Third International Conference ¶“The Adjuvant Therapy of Malignant Melanoma” (1999) (0)
- Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM). (2009) (0)
- Vorwort (2012) (0)
- Vorwort (2013) (0)
- Alpha-MSH is not secreted by B16-OVA melanoma cells or up-regulated in mice bearing B16-OVA tumors. (2013) (0)
- [Sentinel lymph node biopsy]. (2005) (0)
- 26206 Effect of sonidegib on secondary tumor size endpoints through 12 weeks of treatment in patients with nevoid basal cell carcinoma syndrome (2021) (0)
- [Lipoma of the lip. A rare differential diagnosis]. (2002) (0)
- Reply to N. Rompoti et al. (2013) (0)
- 6.4 Interleukin 2 (IL-2) (2010) (0)
- Corrigendum to 'Prediction of melanoma evolution in melanocytic nevi via artificial intelligence: A call for prospective data' [Eur J Cancer, 119 (September 2019) Pages 30-34]. (2019) (0)
- [Cutaneous lymphoma]. (1996) (0)
- Association Between Baseline Disease Characteristics and Relapse-Free Survival in Patients With BRAF V600–Mutant Resected Stage III Melanoma Treated With Adjuvant Dabrafenib + Trametinib or Placebo (2019) (0)
- [Melanocytic nevi]. (2006) (0)
- Nanoemulsion aminolaevulinic acid photodynamic therapy for nonaggressive basal cell carcinoma: a comparison study (2017) (0)
- [EADV-Conference 16.-20.05.2007 in Vienna: Study of new pharmaceuticals 5-ALAPlaster (PD P 506 A)]]. (2007) (0)
- Effect of BRAF Mutation Status on Efficacy of nab-Paclitaxel versus Dacarbazine in Chemotherapy-Naive Patients with Metastatic Melanoma Treated in a Phase III Trsial (2013) (0)
- [Congenital cerebriform nevus cell nevus on the occiput. Removal after tissue expander implantation]. (2001) (0)
- Interaktives Expertenforum Melanom: Juni 2016 (2016) (0)
- Metastatic basal cell carcinoma : Prognosis dependent on anatomic site and spread of disease qq (2014) (0)
- 26211 Pharmacokinetics of sonidegib in patients with nevoid basal cell carcinoma syndrome (2021) (0)
- Temozolomide (TMZ) in combination with pegylated interferon alfa-2b for stage IV metastatic melanoma: A multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). (2016) (0)
- 21. Miscellaneous Reactions (2013) (0)
- 3323 The GERMELATOX DeCOG-trial: The attitude of German melanoma patients towards toxicity during adjuvant interferon treatment - Differences between the patient's and the physician's perspective (2015) (0)
- A phase II multicenter study on CY-503 in the treatment of patients with unresectable stage IV metastatic melanoma after failure of previous chemotherapy. (2010) (0)
- FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the “Melanoma Research: a bridge from Naples to the World. Napoli, December 5th–6 th2011” (2012) (0)
- Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study (2019) (0)
- 814P Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3 (2022) (0)
- Morbidity after radical Lymphadenectomy for Melanoma patients: Influence of the POSSUM Score and a previous Sentinel lymph node removal (2011) (0)
- Sorafenib, a Multikinase Inhibitor: Results from Clinical Trials in Melanoma Patients (2009) (0)
- Feasibility of assessing utilities with a single-item standard gamble questionnaire in patients with melanoma (2021) (0)
- 1241PImpact of duration of response (DOR) on overall survival (OS) in patients with metastatic melanoma treated with dacarbazine (DTIC), vemurafenib (V), or cobimetinib plus vemurafenib (C+V): a pooled analysis (2017) (0)
- [Formalin-resistant leukocyte differentiation antigens in dermatohistopathology]. (1990) (0)
- Pembrolizumab (pembro) plus lenvatinib (len) for first-line treatment of patients (pts) with advanced melanoma: Phase III LEAP-003 study (2019) (0)
- Chemoimmunotherapy in metastatic melanoma: 410 (1997) (0)
- Optimized detection of 5-S-cysteinyldopa (5-S-CD) in serum of melanoma patients: A new marker of metastatic (1997) (0)
- 818P Phase II confirmatory study of cemiplimab (350mg IV Q3W) in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Study 1540 Group 6 (2022) (0)
- 14.3 Kutane Lymphome (2010) (0)
- [Skin changes as a result of targeted therapies in oncology patients: cutaneous side effects of targeted therapies in oncology patients]. (2009) (0)
- Vol. 56, 1999 (1999) (0)
- Outcome on 560 metastatic melanoma (MM) patients treated with pembrolizumab during the German Expanded Access Program (EAP) (2016) (0)
- Diagnostic and treatment standards in dermatological oncology (1998) (0)
- Title Page / Contents / Imprint (2014) (0)
- Vemurafenib in Melanoma with BRAF V600E Mutation REPLY (2011) (0)
- 838P Patterns of response/progressive disease (PD) and management following PD with anti-PD-1 (PD1) in patients (pts) with advanced cutaneous squamous cell carcinoma (cSCC) (2022) (0)
- 6.3 Interferone (2010) (0)
- 3343 Exploratory analysis of vismodegib (VISMO) treatment discontinuation in the STEVIE study (2015) (0)
- 1075P Regression tree analysis to identify factors associated with relapse-free survival (RFS) in patients with resected stage III BRAF V600E/K–mutant melanoma (2021) (0)
- Main Plenary Sessions (2015) (0)
- 3345 COMBI-v: health-related quality of life (HRQoL) impact of the combination of dabrafenib and trametinib (D+T) vs vemurafenib (V) in patients with BRAF V600 metastatic melanoma (MM) (2015) (0)
- Cutaneous Side Effects of combination Therapy with Sorafenib and Peginterferon - an Evaluation of the SoraPeg Study of the ADO (2011) (0)
- 1087P Time to clinically meaningful changes in pain in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab in a phase II clinical trial (2020) (0)
- Response to a costly revolution for a subgroup of patients with metastatic melanoma (2013) (0)
- Targeted therapies in metastatic Melanoma (2011) (0)
- Cisplatin/epinephrine injectable gel for the intralesional treatment of melanoma metastases: Results of a multi-institutional trial (2001) (0)
- 13 Prospective-randomized study on the adjuvant use of s.c. IL-2 and s.c. IFNα2b in high-risk melanoma patients (1999) (0)
- Mission of the Global Melanoma Task Force (2009) (0)
- [Working group of the Dermatologic Oncology]. (2009) (0)
- Cemiplimab Improves Health-Related Quality of Life (HRQoL) and Reduces Pain in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Results from a Post Hoc Exploratory Analysis of a Phase 2 Clinical Trial (2021) (0)
- [Hazards of exposure to the sun]. (1994) (0)
- Skin Toxicities due to Biotherapy (2013) (0)
- [Systemic treatment of melanoma. Current clinical trials]. (2008) (0)
- STEVIE, étude ouverte simple bras pour évaluer la tolérance du vismodegib (V), un inhibiteur de la voie patched sonic hedgehog chez les patients ayant un carcinome basocellulaire (CBC) avancé : analyse sur 150 patients (2012) (0)
- Volume Index 2012 (2012) (0)
- BF‐200 ALA gel vs. MAL cream for BCC (2018) (0)
- Implications for Control and Treatment Through the Hedgehog Pathway (0)
- Vorwort (2011) (0)
- Intralesional rose bengal for stage III and IV melanoma (2016) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Axel Hauschild?
Axel Hauschild is affiliated with the following schools:
